JP2022545815A5 - - Google Patents

Info

Publication number
JP2022545815A5
JP2022545815A5 JP2022513162A JP2022513162A JP2022545815A5 JP 2022545815 A5 JP2022545815 A5 JP 2022545815A5 JP 2022513162 A JP2022513162 A JP 2022513162A JP 2022513162 A JP2022513162 A JP 2022513162A JP 2022545815 A5 JP2022545815 A5 JP 2022545815A5
Authority
JP
Japan
Prior art keywords
cmsd
modified
itam
cells
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545815A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/112181 external-priority patent/WO2021037221A1/en
Publication of JP2022545815A publication Critical patent/JP2022545815A/ja
Publication of JP2022545815A5 publication Critical patent/JP2022545815A5/ja
Pending legal-status Critical Current

Links

JP2022513162A 2019-08-28 2020-08-28 Ｎｅｆ含有Ｔ細胞及びその産生方法 Pending JP2022545815A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019103041 2019-08-28
CNPCT/CN2019/103041 2019-08-28
CNPCT/CN2019/125681 2019-12-16
CN2019125681 2019-12-16
PCT/CN2020/112181 WO2021037221A1 (en) 2019-08-28 2020-08-28 Nef-containing t cells and methods of producing thereof

Publications (2)

Publication Number Publication Date
JP2022545815A JP2022545815A (ja) 2022-10-31
JP2022545815A5 true JP2022545815A5 (enExample) 2023-10-06

Family

ID=74683378

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513891A Pending JP2022547837A (ja) 2019-08-28 2020-08-28 遺伝子操作されたｔ細胞及びその産生方法
JP2022513162A Pending JP2022545815A (ja) 2019-08-28 2020-08-28 Ｎｅｆ含有Ｔ細胞及びその産生方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022513891A Pending JP2022547837A (ja) 2019-08-28 2020-08-28 遺伝子操作されたｔ細胞及びその産生方法

Country Status (12)

Country Link
US (2) US20230085615A2 (enExample)
EP (2) EP4022044A4 (enExample)
JP (2) JP2022547837A (enExample)
KR (2) KR20220066291A (enExample)
CN (3) CN114599785A (enExample)
AU (2) AU2020336791A1 (enExample)
CA (2) CA3150401A1 (enExample)
IL (1) IL290946A (enExample)
MX (1) MX2022002325A (enExample)
TW (2) TW202122574A (enExample)
WO (2) WO2021037222A1 (enExample)
ZA (1) ZA202202127B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2022174172A1 (en) * 2021-02-15 2022-08-18 H. Lee Moffitt Cancer Center And Research Institute Inc. Customized chimeric antigen receptor polypeptides
US20230303655A1 (en) * 2021-10-18 2023-09-28 Kite Pharma, Inc. Signaling domains for chimeric antigen receptors
IL320312A (en) * 2022-10-25 2025-06-01 Kyverna Therapeutics Inc Methods for treating lupus nephritis using anti-cd19 car-t cell therapies
WO2024153211A1 (en) * 2023-01-19 2024-07-25 Nanjing Legend Biotech Co., Ltd. Fusion polypeptides for targeted protein degradation and mehtods of use thereof
WO2024196969A2 (en) * 2023-03-20 2024-09-26 Memorial Sloan-Kettering Cancer Center Cells and compositions for treating cancer
WO2025011459A1 (en) * 2023-07-07 2025-01-16 Nanjing Legend Biotech Co., Ltd. Proteins and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943139B2 (en) * 2004-01-09 2011-05-17 Morehouse School Of Medicine Methods of generating a humoral immune response against human immunodeficiency virus (HIV) comprising administering Nef apoptotic motif-containing polypeptide-conjugates
US11578115B2 (en) * 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN108395481B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
CN110520196A (zh) * 2017-04-19 2019-11-29 艾洛基治疗公司 改进的t细胞组合物和方法
CN109306014B (zh) * 2017-07-27 2022-04-12 上海细胞治疗研究院 一种靶向间皮素的嵌合抗原受体修饰t细胞及其用途
WO2019126358A1 (en) * 2017-12-22 2019-06-27 Cell Design Labs, Inc. Single- and multi-chain chimeric antigen receptors
IL326873A (en) * 2017-12-29 2026-04-01 Memorial Sloan Kettering Cancer Center Enhanced chimeric antigen receptors and uses thereof
US20210023170A1 (en) * 2018-02-12 2021-01-28 University Of Florida Research Foundation, Incorporated Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a

Similar Documents

Publication Publication Date Title
EP3472205B1 (en) Chimeric antigen receptor
JP2023527049A5 (enExample)
JP2022113880A5 (enExample)
JP2022547837A5 (enExample)
KR102607152B1 (ko) 키메라 항원 수용체
JP2022534680A5 (enExample)
JP2023080185A (ja) キメラ抗原受容体
JP2020511136A5 (enExample)
US20230265207A1 (en) T cell-antigen coupler with y182t mutation and methods of uses thereof
US20220348689A1 (en) ADOPTIVE T-CELL THERAPY USING EMPD-SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR TREATING lgE-MEDIATED ALLERGIC DISEASES
JP2021532742A5 (enExample)
JP2022516496A5 (enExample)
CN113388629A (zh) 三功能t细胞抗原偶联物及其制备方法和用途
AU2019307905B2 (en) T cell-antigen coupler with various construct optimizations
US20100143315A1 (en) Method for Improving the Specific Effector Function of Single-Chain Antigen-Recognizing Genetic Constructs (SCARC) Through Murinization Thereof
JP2023512452A (ja) Ｂｃｍａ指向性細胞免疫療法組成物および方法
US20250041343A1 (en) Cd7-car-t cell, its preparation method and the application thereof
WO2020259541A1 (zh) 一种用于肿瘤治疗的嵌合抗原受体t淋巴细胞及其制备方法与应用
JP2025505546A5 (enExample)
WO2020253879A1 (zh) 一种双特异性嵌合抗原受体
EP3898665B1 (en) Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
JP2022526720A5 (enExample)
JP2024534783A5 (enExample)
JP2024507958A5 (enExample)
CA3232203A1 (en) Il5ra cell surface markers